Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bevacizumab with Chemoradiation for Locally Advanced Pancreatic Cancer
NCT00307723Phase 2Terminated
- Sponsor
- Massachusetts General Hospital
- Start
- May 2006
- Primary completion
- Aug 2007
- Modality
- Monoclonal Antibodies
01
Overview
Phase 2, open-label trial of bevacizumab in pancreatic ductal adenocarcinoma (PDAC) (2 arms), sponsored by Massachusetts General Hospital. Primary endpoints: Safety and Tolerability at 2 years and Overall Survival. Started May 2006; status: terminated.
02
Drugs
bevacizumab
03
Conditions
pancreatic ductal adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT00307723.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00307723.